← Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JNGHF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JNGHF)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-10-31 (est.)Phase 3 · SHR6390imp 9/10
- 2026-11-15 (est.)Phase 2 · SHR-A1811 combined with Pyrotinib.imp 7/10
- 2026-12-15 (est.)Phase 2 · HRS-6209 Capsulesimp 7/10
- 2026-12-31 (est.)Phase 2 · entinostatimp 7/10
- 2026-12-31 (est.)Phase 3 · Pyrotinib in combination with Capecitabine.imp 9/10
- 2027-02-15 (est.)Phase 2 · FH-006 for Injectionimp 7/10
- 2027-03-15 (est.)Phase 2 · HRS-4642imp 7/10
- 2027-03-15 (est.)Phase 2 · Rezvilutamideimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| HRS-4357 injection | Phase 3 | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer |
| Propofol Injection. | Phase 2 | Local Anesthesia Assisted Sedation |
| SHR0302 Tablets | Phase 2 | Non-segmental Vitiligo |
| Apatinib | Phase 3 | Carcinoma, Hepatocellular |
| APL-1202 treatment | Phase 2 | Non-muscle Invasive Bladder Cancer |
| RSS0343 Tabella | Phase 2 | Adolescent Asthma |
| X0002 Spray | Phase 3 | KNEE OSTEOARTHRITIS |
| SHR-1020 | Phase 2 | Recurrent or Metastatic Cervical Cancer |
| KN026 combination | Phase 2 | HER2-positive Solid Tumors |
| mFOLFIRINOX | Phase 2 | Advanced Pancreatic Cancer |
| benzbromarone | Phase 2 | Hyperuricemia |
| JSKN016 | Phase 2 | Inoperable Locally Advanced HER2-Negative Breast Cancer |
| SHR2554/CHOP | Phase 2 | Peripheral T-cell Lymphoma |
| SP2086(50 mg q.d.)/Metformin | Phase 2 | Type 2 Diabetes |
| KN019, 5mg/kg | Phase 2 | Rheumatoid Arthritis |
| HR18042 | Phase 2 | Moderate to Severe Acute Pain |
| KN026 10 mg/kg QW | Phase 2 | Gastric/Gastroesophageal Junction Cancer |
| JSKN003 | Phase 3 | Advanced Solid Tumor |
| Irinotecan liposome、5-Fluorouracil、Leucovorin | Phase 3 | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy |
| Propofol Medium and Long Chain Fat Emulsion Injection | Phase 3 | Sedation in the ICU |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$5.80–$6.10
vs 50-day MA
—
vs 200-day MA
—
Realized vol
11.1%
Max drawdown
-4.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for JNGHF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.